Table 3 Quantitative analysis of DNMT3A R882H in follow-up samples from 6 AML patients
From: Quantitative detection of DNMT3A R882H mutation in acute myeloid leukemia
Patient | Age/Gender | FAB | Karyotype | Mutations at diagnosis | Disease status | DNMT3A % | NPM1 log | FLT3 Ratio | Outcome/OS |
|---|---|---|---|---|---|---|---|---|---|
1 | 52/F | M4 | 46,XX | NPM1 | DS | 21,45 | 1^106 | 0,72 | CR/9+ |
FLT3-ITD | CR after CT | 16,4 | 1^-5 | 0 | |||||
FLT3-TKD2 | CR, day+28 after alloSCT , CDC | 0 | 0 | 0 | |||||
DNMT3A | CR, day+195 after alloSCT, CDC | 0 | 0 | 0 | |||||
2 | 60/M | M2 | 46,XY, del(9q) | NPM1 | DS | 11,95 | 1^105 | Â | CR/31+ |
DNMT3A | CR after IT | 5,8 | 1^10-2 | Â | |||||
CR after CT | 0,05 | 1^10-4 | Â | ||||||
CR, Platelet ↓ | 0,1 | 1^10-4 |  | ||||||
CR | 16,5 | 1^10-5 | Â | ||||||
CR | 30,8 | 0 | Â | ||||||
CR | 11,3 | 1^10-4 | Â | ||||||
CR, day+26 after alloSCT, 98Â %Â DC | 0 | 0 | Â | ||||||
CR, day+73 after alloSCT (CDC) | 0 | 0 | Â | ||||||
3 | 43/F | M4 | 46,XX | NPM1 | DS | 17,9 | 1^105 | 0,78 | CR/52+ |
FLT3-ITD | CR, day+563 after alloSCT, CDC | 0 | 1^10 -5 | 0 | |||||
DNMT3A | CR, day+731 after alloSCT, CDC | 0 | 1^10 -4 | 0 | |||||
CR, day+1082 after alloSCT, CDC | 0 | 0 | 0 | ||||||
CR, day+1445 after alloSCT, CDC | 0 | 0 | 0 | ||||||
4 | 50/M | M4 | 46,XY | NPM1 | DS | 14,95 | 1,0^105 | 0,41 | R/17+ |
FLT3-ITD | CR after IT | 1,6 | 1^10-4 | 0 | |||||
DNMT3A | CR after CT | 1,2 | 1^10-5 | 0 | |||||
CR, day+40 after alloSCT, CDC) | 0 | 1^10 -4 | 0 | ||||||
CR, day+130 after alloSCT, CDC | 0,1 | 0 | 0 | ||||||
CR, day+217 after alloSCT, CDC | 0 | 0 | 0 | ||||||
R, day+306 after alloSCT, 10Â %Â DC | 9,25 | 1^10 5 | 0 | ||||||
R, day+373 after alloSCT, 15Â %Â DC | 11,7 | 1^10 4 | 0,25 | ||||||
5 | 50/F | 5a | 46,XX | NPM1 | DS | 22,15 | 1^105 | 0,5 | CR/26 |
FLT3-ITD | CR after IT | 0,35 | 1^10-4 | 0 | |||||
DNMT3A | CR after IT | 0,2 | 1^10-4 | 0 | |||||
IDH1 | CR after CT | 0,1 | 1^10-4 | 0 | |||||
CR after CT | 0,05 | 0 | 0 | ||||||
CR, day+29 after alloSCT, CDC | 0,05 | 1^10 -4 | 0 | ||||||
CR, day+71 after alloSCT, CDC | 0 | 1^10 -5 | 0 | ||||||
R, day+114 after alloSCT, 90Â %Â DC | 0,05 | 1^10 -4 | 0 | ||||||
CR, day+174 after alloSCT, CDC | 0 | 0 | 0 | ||||||
CR, day+215 after alloSCT, CDC | 0 | 0 | 0 | ||||||
6 | 71/M | 5a | 46,XY | NPM1 | DS | 12,75 | 1^104 | Â | CR/46+ |
DNMT3A | CR after IT | 0,1 | 1^10-2 | Â | |||||
IDH1 | CR after CT | 0,1 | 1^10-4 | Â | |||||
IDH2 | CR after CT | 1,65 | 1^10-4 | Â | |||||
CR | 0,1 | 1^10-4 | Â | ||||||
CR | 4,05 | 1^10-4 | Â | ||||||
CR | 0,5 | 0 | Â | ||||||
CR | 0 | 0 | Â | ||||||
CR | 0 | 1^10-4 | Â | ||||||
R | 2 | 1^10-2 | Â | ||||||
R | 0,5 | 1^104 | Â | ||||||
2.CR | 0 | 1^10-4 | Â | ||||||
2.CR | 0,05 | 1^10-3 | Â | ||||||
CR, day+27 after alloSCT, 92Â %Â DC | 0 | 1^10 -4 | Â | ||||||
CR, day+80 after alloSCT, 60Â %Â DC | 0,45 | 0 | Â | ||||||
CR, day+91 after alloSCT, 65Â %Â DC | 0,15 | 1^10 -4 | Â | ||||||
CR, day+208 after alloSCT 14Â %Â DC | 1,25 | 0 | Â | ||||||
CR, day+279 after alloSCT, CDC | 0 | 0 | Â | ||||||
CR, day+570 after alloSCT, CDC | 0 | 0 | Â |